BG
DMRA

Bellevue Group’s Damora Therapeutics DMRA Stock Holding History

Bellevue Group’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59.5M Buy
+2,298,000
New +$59.1M 1.42% 25

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Bellevue Group's DMRA Position: Q1 2026 in Review

Bellevue Group opened a new position in Damora Therapeutics (DMRA) in Q1 2026: 2,298,000 shares worth $59.5M. The stake represents 1.42% of the portfolio and ranks #25 among its holdings.

65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • Bellevue Group held 2,298,000 shares of Damora Therapeutics worth $59.5M as of Q1 2026.
  • Damora Therapeutics was a new Bellevue Group position in Q1 2026.
  • Damora Therapeutics made up 1.42% of Bellevue Group's portfolio in Q1 2026, its #25 holding.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.